---
title: "Compass Therapeutics Q2 2026 net loss widens 26.63% to $25.2 million; R&D expenses rise 19% to $19.6 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295100372.md"
description: "Compass Therapeutics reported a Q2 2026 net loss of $25.2 million, widening 26.63% from the prior year, despite an improvement in loss per share to $0.13. R&D expenses rose 19% to $19.6 million due to increased spending on tovecimig, while G&A costs climbed 59% to $7.4 million. The company holds $180 million in cash and expects funding into 2028, with FDA feedback anticipated in Q3 regarding tovecimig BTC data."
datetime: "2026-08-06T11:31:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295100372.md)
  - [en](https://longbridge.com/en/news/295100372.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295100372.md)
generator: "portal-rs"
---

# Compass Therapeutics Q2 2026 net loss widens 26.63% to $25.2 million; R&D expenses rise 19% to $19.6 million

-   Compass Therapeutics posted a Q2 net loss of USD 25.2 million, widening from USD 19.9 million a year earlier. \* Loss per share was USD 0.13, improving from USD 0.14 in the prior-year quarter. \* R&D expense rose 19% to USD 19.6 million, driven primarily by USD 2.6 million higher tovecimig-related spending. \* G&A expense climbed 59% to USD 7.4 million on USD 1.4 million higher pre-commercialization costs and USD 0.8 million higher stock compensation. \* Cash and marketable securities totaled USD 180 million at June 30, with management expecting funding into 2028 and FDA feedback in Q3 on tovecimig BTC data. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005292), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Goobit Group sells 3 BTC for SEK 2.22 million from bitcoin treasury](https://longbridge.com/en/news/297923542.md)
- [Biotechnology Assets names Maguenei Pari to board, replacing John Dixon](https://longbridge.com/en/news/297545580.md)
- [BTC Digital receives Nasdaq notice after shares trade below $1 for 30 days](https://longbridge.com/en/news/297827353.md)
- [DL Holdings says it sells 405 bitcoin for USD 29.98 million in mining update](https://longbridge.com/en/news/297920342.md)
- [Key facts: CRYPTO:BTCUSD levels; Company 845,050 BTC; River 10% advice](https://longbridge.com/en/news/297912416.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**